The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...
34mon MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and ...
Poor earnings results and a slump in the major gauges leave the weekend uncertain as futures hug the flatline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results